Javier Cortes on KEYNOTE-119 Trial of Pembrolizumab vs Chemotherapy in TNBC – The ASCO Post

Javier Cortes, MD, PhD, of the IOB Institute of Oncology, discusses study findings that suggested pembrolizumab offered a prolonged survival benefit compared to chemotherapy for a subset of patients with previously treated metastatic triple-negative breast cancer. In the trial, high tumor-infiltrating lymphocytes were significantly associated with better clinical outcomes with the checkpoint…

Read the full article here

Related Articles